WhiteOak Capital Pharma and Healthcare Fund Direct Growth

WhiteOak Capital Pharma and Healthcare Fund Direct Growth

Equity

WhiteOak Mutual Fund

Sector - Healthcare

Get the latest NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth. View historical returns compared to its benchmark and category average. Know which stocks and sectors the fund is investing in. Get an estimate of returns from the SIP and lump sum returns calculator. View detailed holding analysis and peer comparison. Get INDmoney ranking of the fund.

₹13.11

▲0.8%1D

NAV as on 14 May 2025

23.6%/per year

Since Inception

Absolute Gain%

▲▼

566 people have invested ₹ 36L in WhiteOak Capital Pharma and Healthcare Fund Direct Growth in the last three months

WhiteOak Capital Pharma and Healthcare Fund Performance vs. Nifty 500

Fund returns vs Benchmark returns vs Category Average returns as on (14-May-25)

The fund has outperformed the benchmark (Nifty 500) over 1Y, but underperformed over 3Y, 5Y.

Period
This Fund
Nifty 500
Category Avg
1 Month
4.14%
7.69%
4.25%
3 Months
1.97%
6.91%
1.94%
6 Months
1.86%
1.98%
-1.2%
1 Year
28.81%
8.96%
18.11%

Peer comparison

Fund Name
INDmoney Rank
AUM (in Crs.)
Expense Ratio
1Y Returns
3Y Returns
Inception Returns
WhiteOak Capital Pharma and Healthcare Fund
-
304Cr
0.68%
28.81%
-
23.6%
SBI Healthcare Opportunities Fund Direct Growth
1/8
3,671Cr
0.9%
21.31%
28.45%
18.18%
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
3/8
4,915Cr
1.11%
23.62%
28.36%
22.59%
DSP Healthcare Fund Direct Growth
4/8
2,912Cr
0.63%
13.3%
24.22%
24.13%
See all

WhiteOak Capital Pharma and Healthcare Fund Returns Calculator

Calculate SIP and lumpsum returns based on historical performance

  • 1-time

  • SIP

Total Investment

0

Profit

Total Corpus

0

Absolute Return
▲
▼

WhiteOak Capital Pharma and Healthcare Fund Asset Allocation

See fund asset allocation details as on (15-Apr-25)

Fund Distribution

as on (15-Apr-25)

Equity 93.3%

Debt & Cash 6.7%

Small cap
32.4%
Large cap
31.1%
Mid cap
29.1%
Large Cap allocation has gone down from 29.5% to 28.7%
Large Cap allocation has gone down from 29.5% to 28.7%
Small Cap allocation has gone up from 28.6% to 34.7%
Small Cap allocation has gone up from 28.6% to 34.7%
Mid Cap allocation has gone down from 32.6% to 27.2%
Mid Cap allocation has gone down from 32.6% to 27.2%
Cash allocation has gone down from 7.3% to 7.1%
Cash allocation has gone down from 7.3% to 7.1%

WhiteOak Capital Pharma and Healthcare Fund Sector Allocation

See fund sector allocation details as on (15-Apr-25)

Sector Allocation

Equity 93.3%

Debt & Cash 6.7%

Health
96.4%
Basic Materials
3.6%

Top 3 Sectors in March were Health, Basic Materials & Industrial

Mar'25

Health

95%

Basic Materials

4%

Financial Services

Feb'25

Health

96%

Basic Materials

3%

Industrial

WhiteOak Capital Pharma and Healthcare Fund Holdings Details

as on (30-Apr-25)

Equity

Debt & Cash

Top Stocks bought last month
Laurus Labs Ltd's allocation increased from 2.36% to 3.54%
Laurus Labs Ltd's allocation increased from 2.36% to 3.54%
Krishna Institute of Medical Sciences Ltd's allocation increased from 3.08% to 3.85%
Krishna Institute of Medical Sciences Ltd's allocation increased from 3.08% to 3.85%
Piramal Pharma Ltd's allocation increased from 2.02% to 2.72%
Piramal Pharma Ltd's allocation increased from 2.02% to 2.72%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 8.07 % to 7.39 %
Cipla Ltd's allocation decreased from 8.07 % to 7.39 %
Divi's Laboratories Ltd's allocation decreased from 7.03 % to 6.08 %
Divi's Laboratories Ltd's allocation decreased from 7.03 % to 6.08 %
Max Healthcare Institute Ltd Ordinary Shares's allocation decreased from 7.41 % to 5.14 %
Max Healthcare Institute Ltd Ordinary Shares's allocation decreased from 7.41 % to 5.14 %

WhiteOak Capital Pharma and Healthcare Fund Direct Growth Overview

Get key fund statistics, minimum investment details, AUM, expense ratio, exit load, and tax treatment.

Expense ratio0.68%
Benchmark
BSE Healthcare TR INR
AUM₹304 Cr
Inception Date6 February, 2024
Min Lumpsum/SIP₹500/₹100
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
73.27%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

About WhiteOak Capital Pharma and Healthcare Fund

WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 6 February, 2024. The fund is managed by Piyush Baranwal. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. WhiteOak Capital Pharma and Healthcare Fund Direct Growth has ₹304 Cr worth of assets under management (AUM) as on Mar 2025 and is less than category average.
  2. The fund has an expense ratio 0.7.

Returns

WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 23.60% since inception. Over the last 1 year the fund has given a CAGR return of 28.81%.

Holdings

WhiteOak Capital Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent, Government, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Divi's Laboratories Ltd, Max Healthcare Institute Ltd Ordinary Shares, Lupin Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

Investment objective of WhiteOak Capital Pharma and Healthcare Fund Direct Growth

The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 500.00 and for SIP is INR 100.00. WhiteOak Capital Pharma and Healthcare Fund Direct Growth has no lock in period.

Fund Manager

Piyush Baranwal

Fund Manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, since 6 February 2024

Learn more about WhiteOak Mutual Fund
Parameters
Mar'25
Feb'25
Jan'25
AUM
₹ 303.6 Cr
₹ 271.4 Cr
₹ 282.6 Cr
  • AUM of the fund stands at 303.6 Cr as of Mar'25
  • AUM increased by 32.3 Cr between Mar'25 and Feb'25

Frequently Asked Questions for WhiteOak Capital Pharma and Healthcare Fund Direct Growth

What is the current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

The current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is ₹13.11 as on 14-May-2025.

What are the average returns of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

Existing (Absolute + CAGR) as on 14-May-2025.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
4.14%
4.14%
6 Month Returns
1.86%
1.86%
1 Year Returns
28.81%
28.81%
3 Years Returns
0%
0%

How do I invest in WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.

What is the expense ratio of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

0.68% as on April 2025

What is net assets under management (AUM) of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

₹304 Cr as on April 2025

What are the top 5 holdings of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

Sun Pharmaceuticals Industries Ltd(11.31%), Cipla Ltd(7.57%), Divi's Laboratories Ltd(7.37%), Max Healthcare Institute Ltd Ordinary Shares(7.17%), Lupin Ltd(5.37%) as on April 2025

What are the top 3 sectors that this WhiteOak Capital Pharma and Healthcare Fund Direct Growth has invested in?

Health(89.19%), Basic Materials(3.59%), Financial Services(0.53%) as on April 2025

What is the alpha of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

The alpha ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
8
-
-
As on April 2025
The alpha for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated against BSE Healthcare TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.

What is the beta of WhiteOak Capital Pharma and Healthcare Fund Direct Growth??

The Beta ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
1
-
-
As on April 2025
The Beta for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.

What is the sharpe ratio of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

The sharpe ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
1.03
-
-
As on April 2025
The sharpe ratio for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.

What is the standard deviation of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

The standard deviation for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
20.35
-
-
As on April 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.

Who is the manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

Piyush Baranwal is the fund manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth

What is the exit load of WhiteOak Capital Pharma and Healthcare Fund Direct Growth?

The Exit load of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is 1%